Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination.
Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination.
复制标题
DOI：
10.1038/s41541-022-00439-3
复制
发表时间：
2022-02-08
期刊：
影响因子：
9.2
通讯作者：
Oshiumi H
中科院分区：
文献类型：
--
作者：
Miyashita Y;Yoshida T;Takagi Y;Tsukamoto H;Takashima K;Kouwaki T;Makino K;Fukushima S;Nakamura K;Oshiumi H
基于mRNA的疫苗已在全球范围内用于根除2019年冠状病毒病（COVID-19）大流行。疫苗效力和不良反应取决于免疫应答，例如促炎细胞因子产生和淋巴细胞活化。我们进行了一项前瞻性队列研究，以调查COVID-19疫苗接种（BNT 162 b2）后血清细胞外囊泡（EV）中特异性抗体滴度、不良反应、促炎细胞因子产生和免疫调节microRNA（miRNA）水平之间的关系。第二次给药后的局部不良反应（如局部疼痛和肿胀）与全身症状（如发热和肌肉疼痛）的相关性较小，而血清TNF-α水平与全身不良反应和特异性抗体滴度相关。有趣的是，血清中EV miR-92 a-2- 5 p水平与不良反应程度呈负相关，EV miR-148 a水平与特异性抗体滴度相关。我们的数据表明，循环EV miRNA作为疫苗有效性和不良反应的生物标志物的潜力。
mRNA-based vaccines have been used globally to eradicate the coronavirus-disease 2019 (COVID-19) pandemic. Vaccine efficacy and adverse reactions depend on immune responses, such as proinflammatory cytokine production and lymphocyte activation. We conducted a prospective cohort study to investigate relationships among specific antibody titers, adverse reactions, proinflammatory cytokine production, and immune-regulatory microRNA (miRNA) levels in serum extracellular vesicles (EVs) after COVID-19 vaccination (BNT162b2). Local adverse reactions after the second dose, such as local pain and swelling, were less correlated with those of systemic symptoms, such as fever and muscle pain, whereas serum TNF-α levels were associated with systemic adverse reactions and with specific antibody titers. Interestingly, EV miR-92a-2-5p levels in sera were negatively correlated with degrees of adverse reactions, and EV miR-148a levels were associated with specific antibody titers. Our data suggest a potential of circulating EV miRNAs as biomarkers for vaccine efficacy and adverse reactions.
登录
查看更多内容
影响因子：
158.5
作者：
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者：
Feng, Zijian
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
5.6
作者：
Kouwaki T;Okamoto M;Tsukamoto H;Fukushima Y;Oshiumi H
通讯作者：
Oshiumi H
影响因子：
56.9
作者：
Mata-Haro, Veronica;Cekic, Caglar;Mitchell, Thomas C.
通讯作者：
Mitchell, Thomas C.
影响因子：
6.4
作者：
Dinarello, CA
通讯作者：
Dinarello, CA